0034 GMT - Cochlear's expectation of FY 2027 profit growth appears to be driven by operating costs rather than sales, Jarden analysts observe. They tell clients in a note that the hearing-implant maker's guidance for 5.5% net profit growth at the range midpoint comes despite its expectation that sales revenue will only grow by a percentage in the low single digits. They tell clients in a note that the profit guidance, which is in line with analysts' expectations, is supported by a slight on-year decline in operating costs. They think that the quality of the FY 2026 result was worse than anticipated, but see the FY 2027 outlook as positive. Jarden has a last-published neutral rating on the stock and a target price of 169.00 Australian dollars. Shares are up 5.0% at A$137.80.